Sep.—In their second alliance this year, microRNA specialist Rosetta Genomics and the NYU Medical Center have agreed to screen these smaller nucleic acid molecules for a biomarker of melanoma.
NYU scientists, including Nina Bhardwaj, MD, PhD, will contribute their expertise in this type of cancer, while Rosetta is in charge of screening over 700 miRNAs--a number of which were...